These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16166989)

  • 1. A comparison of pegfilgrastim and filgrastim.
    Grigg AP
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):176, 179-80. PubMed ID: 16166989
    [No Abstract]   [Full Text] [Related]  

  • 2. Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy.
    Ng R; Green MD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):585-90. PubMed ID: 16111460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Filgrastim and pegfilgrastim use in patients with neutropenia.
    Quirion E
    Clin J Oncol Nurs; 2009 Jun; 13(3):324-8. PubMed ID: 19502191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
    Waladkhani AR
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients.
    Chan A; Leng XZ; Chiang JY; Tao M; Quek R; Tay K; Lim ST
    Asia Pac J Clin Oncol; 2011 Mar; 7(1):75-81. PubMed ID: 21332654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients.
    Martino M; Praticò G; Messina G; Irrera G; Massara E; Messina G; Console G; Iacopino P
    Eur J Haematol; 2006 Nov; 77(5):410-5. PubMed ID: 16930141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
    Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Ratiograstim (biocompatible filgrastim)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):177-8. PubMed ID: 19581185
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the management of chemotherapy-induced neutropenia.
    Crawford J
    J Support Oncol; 2004; 2(2 Suppl 2):36-9. PubMed ID: 16108418
    [No Abstract]   [Full Text] [Related]  

  • 18. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
    Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer.
    Waller CF; Semiglazov VF; Tjulandin S; Bentsion D; Chan S; Challand R
    Onkologie; 2010; 33(10):504-11. PubMed ID: 20926897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuelasta versus G-CSF in solid tumours.
    Green M
    Ann Hematol; 2004; 83 Suppl 1():S57-8. PubMed ID: 15124673
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.